Regeneron Pharmaceuticals

Regeneron Pharmaceuticals logo
🇺🇸United States
Ownership
Public
Established
1988-01-01
Employees
13.4K
Market Cap
$132.4B
Website
http://www.regeneron.com
Introduction

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...

investing.com
·

Maia Biotechnology director Ramiro Guerrero buys $99998 in stock

Ramiro Guerrero, MAIA Biotechnology director, bought 53,418 shares at $1.872 each, totaling $99,998. MAIA expanded its Phase 2 THIO-101 trial for THIO with Regeneron's Libtayo® in third-line NSCLC. Interim results show 10.6-month median survival vs. 5.8 months for standard care.
drugs.com
·

FDA Revokes EUA for REGEN-COV (casirivimab and imdevimab) for the Treatment of COVID-19

FDA revoked EUA for REGEN-COV (casirivimab and imdevimab) on Nov 25, 2024, as all lots expired, and Regeneron no longer offers it in the U.S. due to non-susceptible SARS-CoV-2 variants.
globenewswire.com
·

Global Breakthrough Therapy Designation Market Set to

The Breakthrough Therapies Market was valued at USD 150.6B in 2024, projected to reach USD 287.5B by 2029, growing at a CAGR of 13.80%. The report analyzes BTD's risks, benefits, fast-track drug development, therapy areas, leading companies, and market dynamics.

Roche wins Vabysmo prefilled syringe EU approval to intensify Eylea challenge

EMA approves Roche's Vabysmo prefilled syringe for nAMD, DME, and RVO, aiming to challenge Regeneron's Eylea in the ophthalmologic market. Vabysmo sales grew 324% to $2.64bn, while Eylea's sales declined 3% to $9.38bn. GlobalData forecasts Vabysmo to reach $8.78bn by 2030, with Eylea projected at $2bn.
medcitynews.com
·

ASH 2024 Recap: Movement in Multiple Myeloma, Cell Therapy, Sickle Cell Disease & More

ASH 2024 highlights include GSK's Blenrep Phase 3 data supporting re-market, J&J's Darzalex Faspro delaying progression in smoldering multiple myeloma, Arcellx's anito-cel showing comparable safety to Carvykti, and J&J/Legend's Carvykti improving survival outcomes. Kura Oncology's ziftomenib showed high response rates in leukemia, Eli Lilly's Jaypirca reduced disease progression risk, and Merck's zilovertamab vedotin achieved high complete response rates in lymphoma. Beam Therapeutics' BEAM-101 showed durable effects in sickle cell disease, Novo Nordisk's etavopivat reduced crises, and Bristol Myers Squibb's arlo-cel demonstrated durable responses in multiple myeloma. Galapagos' GLPG5101 showed encouraging cell therapy results, Orca Bio's Orca-T improved survival in blood cancers, and Sanofi's rilzabrutinib improved platelet response in thrombocytopenia. Regeneron's drug combo showed better disease control than Ultomiris in PNH.
pharmavoice.com
·

Regeneron's R&D approach scores dual wins against Alexion's Ultomiris and in lymphoma

Regeneron achieved significant trial results at the American Society for Hematology meeting, demonstrating better disease control in paroxysmal nocturnal hemoglobinuria with a combination therapy and potential best-in-class performance in follicular lymphoma with a bispecific antibody. Dr. Andres Sirulnik highlights Regeneron's science-driven approach and the company's focus on addressing difficult-to-treat problems in hematology.
dovepress.com
·

Understanding the Practical and Psychological Barriers to Clinical Trials

A global survey on clinical trial diversity identified barriers like fear of side effects, lack of knowledge, and financial constraints. Despite high willingness, only 23.9% had participated. Solutions include reducing time commitments, financial reimbursements, and improving information access to increase diversity in trials.
openpr.com
·

PD-1 Non-Small Cell Lung Cancer Treatment Market 2034: EMA

DelveInsight's report on PD-1 Non-Small Cell Lung Cancer Market (2020-2034) highlights market growth, approvals, prevalence, therapies, and companies like Merck, Bristol-Myers Squibb, Genentech, and others. Key therapies include KEYTRUDA, OPDIVO, TECENTRIQ, and TIZVENI. Market drivers include premium-priced targeted agents and therapy expansion, while barriers include premium pricing of emerging therapies.

Regeneron's Ordspono faces challenges, but positive results signal hope

Regeneron's Ordspono shows promise in treating r/r MZL with 77.1% ORR and CR rate, but faces challenges like low long-term adherence and regulatory delays. It received EU approval for r/r FL and DLBCL, but US market adoption is pending confirmatory trials. Competitors like AbbVie and Genmab's Epkinly pose threats with more convenient administration routes.
© Copyright 2024. All Rights Reserved by MedPath